# Coexistence of Hypertrophic Cardiomyopathy and Arterial Hypertension: Current Insights and Future Directions

## TL;DR

This paper reviews how the coexistence of hypertrophic cardiomyopathy and hypertension affects diagnosis and treatment, highlighting the need for further research.

## Contribution

The paper provides a narrative review focusing on the clinical implications and management challenges of combined HCM and hypertension.

## Key findings

- Patients with both HCM and hypertension are older and have more comorbidities and functional limitations.
- Hypertension complicates diagnosis and is linked to higher rates of atrial fibrillation and stroke.
- β-blockers and non-dihydropyridine calcium channel blockers are preferred treatments, while novel agents require further study.

## Abstract

Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Arterial hypertension represents the leading modifiable risk factor for cardiovascular morbidity and mortality globally. Their coexistence is frequent, affecting approximately 40–60% of adults with HCM, yet the implications of this overlap remain insufficiently investigated. Methods: We conducted a narrative review of the existing literature addressing the clinical profile and management strategies in patients with concomitant HCM and hypertension. Particular emphasis was placed on pharmacologic treatment and the role of emerging therapies for this population. Results: Patients with both conditions are generally older, with more cardiometabolic comorbidities and greater functional limitation than those with isolated HCM. Hypertension may confound diagnosis and is linked to a higher prevalence of atrial fibrillation and stroke. Its effect on ventricular arrhythmias, sudden cardiac death and mortality is less clear. Management is challenging, as vasodilatory antihypertensives can exacerbate left ventricular outflow tract obstruction. β-blockers and non-dihydropyridine calcium channel blockers are preferred, while novel agents such as myosin inhibitors and SGLT2 inhibitors show potential but require further study. Conclusions: The coexistence of HCM and hypertension is frequent but insufficiently studied, with major implications for diagnosis and treatment. Further research is essential to optimize management and outcomes.